CROMSOURCE Adds Early Phase Research Unit to its Portfolio
CROMSOURCE srl, an international full service contract research organization announced the completion of a private-public deal with Centro Ricerche Cliniche di Verona (CRC), a modern early phase clinical research unit, founded in 2005. The CRC is located in Verona and is now under state and CROMSOURCE ownership.
The early phase clinical research facilities of the CRC occupy about 800 square metres of the 8th floor of the G.B. Rossi Hospital in Verona. The CRC provides full overnight accommodation and is equipped to state-of-the-art levels. Staff at the CRC has extensive international Pharma experience and the CRC is fully integrated within the local medical and scientific community. This provides access to highly motivated, well-defined patient populations and disease groups for Proof-of-Concept studies.
'We are delighted to welcome CRC and its expert team', stated Dr Oriana Zerbini, Chief Executive Officer of CROMSOURCE. 'For some time we have wanted to add early phase clinical trial capabilities to our comprehensive portfolio of services, and we have now found the perfect way to do so. With this collaboration CROMSOURCE truly becomes a full service CRO, able to provide our customers our support from the earliest part of their clinical development programs.'
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
STEP UP Trial Shows Semaglutide 7.2 mg Achieves Superior Weight Loss vs. 2.4 mg, Placebo
January 17th 2025Semaglutide 7.2 mg significantly outperformed semaglutide 2.4 mg and placebo with a 20.7% average reduction in weight and a comparable safety and tolerability profile, further establishing its efficacy in obesity treatment.
